On September 6, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapiesfor cancer and autoimmune disease, reported that its management will participate in the following upcoming investor conferences in September (Press release, Immutep, SEP 6, 2023, View Source [SID1234634915]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• The 18th Annual Citi Biopharma Conference in Boston, MA on Thursday, September 7.
• Bell Potter Emerging Ideas Leaders Conference on September 12. Presentation at 3:30 p.m. AEST.
• Baird’s 2023 Global Healthcare Conference in New York City, NY on September 12. Fireside chat at 3:45 p.m. ET.
• E&P Small Cap Healthcare Conference in Sydney, NSW. Presentation on September 13 at 4:25 p.m. AEST.
• 2023 Cantor Global Healthcare Conference in New York City, NY on September 26.

Panel presentation at 2:45 p.m. ET. Further information about upcoming conferences and events that Immutep’s management will be attending is available at the Events page within the Investors & Media section of Immutep’s website.